Chiltern acquires Japanese CRO

By Melissa Fassbender

- Last updated on GMT

Integrated Development Associates Co. Ltd. (IDA) specializes in integrating Japan and Asia into global drug development. (Image: iStock/Kritchanut)
Integrated Development Associates Co. Ltd. (IDA) specializes in integrating Japan and Asia into global drug development. (Image: iStock/Kritchanut)

Related tags Asia-pacific Clinical trial

Chiltern has acquired Integrated Development Associates Co. Ltd. (IDA), a Japenese contract research organization (CRO) with offices in Japan, Korea, and Southeast Asia.

IDA was founded in 2004 and provides a variety of services including product development consulting, clinical development, and commercialization.

Following completion of the acquisition, IDA will operate as a wholly owned subsidiary of Chiltern.

John Winebarger, IDA’s founder and CEO will continue to lead the company, which will be renamed IDA, a Chiltern Company.

IDA will enable Chiltern to grow in the APAC region as well as open the door to more opportunities globally, our clients will now have more options for conducting clinical research in the Asia-Pacific region​,” Jim Esinhart, Ph.D., Chiltern CEO told Outsourcing-Pharma.com.

"Our commitment to collaboration and projects focused on our clients’ needs are well supported by the addition of offices in Japan and additional resources in the Philippines​," he added.

SAKIGAKE Designation

The Ministry of Health, Labor, and Welfare (MHLW​) established new regulations known as SAKIGAKE​ (or the “Forerunner Initiative”) in 2015. The approval pathway was designed to accelerate the drug development and approval process in Japan.

According to the company’s website​, IDA obtained SAKIGAKE Designation in 2015, which provides a variety of benefits including shortened review times, priority NDA review, among others.

Global expansion

Earlier this year Chiltern also expanded​ its presence in India with a new process and technology center in Bangalore. The new center supports the company’s analytics, risk-based optimization, biometrics, and pharmacovigilance capabilities. 

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us

Products

View more

Webinars